Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy

Journal of Applied Physiology

Volumn 94, Issue 5, 2003, Pages 2051-2057

  He, Qing ^a   Engelson, Ellen S ^a   Albu, Jeanine B ^a   Heymsfield, Steven B ^a   Kotler, Donald P ^a,b  

^a Columbia University ^*  (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Body composition; Fat redistribution; Human immunodeficiency virus; Intra abdominal adipose tissue; Retroperitoneal adipose tissue; Visceral adipose tissue

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN GROWTH HORMONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BODY FAT; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; FAT CONTENT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; MALE; MESENTERY; METABOLIC DISORDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OMENTUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEUM; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

EID: 0037405673     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.00845.2002     Document Type: Article

References (28)

1. Abate N, Garg A, Peshock RM, Stray-Gundersen J, and Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 96: 88-98, 1995.
2. Barzilai N, She L, Liu BQ, Vuguin P, Cohen P, Wang J, and Rossetti L. Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 48: 94-98, 1999.
3. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, and Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998.
4. Dong KL, Bausserman LL, Flynn MM, Dickinson BP, Flanigan TP, Mileno MD, Tashima KT, and Carpenter CC. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HARRT). J Acquir Immune Defic Syndr Hum Retrovirol 21: 107-113, 1999.
5. Engelson ES, Kotler DP, Tan YX, Wang J, Pieson RN, and Heymsfield SB. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole body magnetic resonance imaging. Am J Clin Nutr 69: 1162-1169, 1999.
6. Engelson ES, Glesby MJ, Mendez D, Albu JB, Wang J, Heymsfield SB, and Kotler DP. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 30: 379-391, 2002.
7. Garg A, Fleckenstein JL, Peshock RM, and Grundy SM. Peculiar distribution of adipose tissue in patients with congenital generalized lipodystrophy. J Clin Endocrinol Metab 75: 358-361, 1992.
8. Gerrior J, Kantaros J, Coakley E, Albrecht M, and Wanke C. The fat redistribution syndrome in patients infected with HIV: measurements of body shape abnormalities. J Am Diet Assoc 101: 1175-1180, 2001.
9. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, and Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32: 130-139, 2001.
10. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, and Bengtsson BA. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82: 727-734, 1997.
11. Kotler DP, Munrahaienen N, Chang P, Engelson ES, Wang J, Heymsfield SB, and Gertner JG. Anthropometric equations selected HIV+ men and women with distinctly abnormal fat accumulation and distribution (Abstract). Int. AIDS Conf. XIVth Barcelona, Spain, July 7-12, 2002, p. WePeB5997.
12. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, Glueck DH, Gourley PJ, Stamm ER, Scherzinger AL, and Eckel RH. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 15: 1993-2000, 2001.
13. LaFranchi S, Hanna CE, Torresani T, Schoenle E, and Illig R. Comparison of growth hormone binding and metabolic response in rat adipocytes of epididymal, subcutaneous, and retroperitoneal origin. Acta Endocrinol 110: 50-55, 1985.
14. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, and Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J 289: 1257-1261, 1984.
15. Lohman TG, Roche AF, and Martello R. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics, 1988.
16. Lo JC, Mulligan K, Noor MA, Schwarz J, Halvorsen RA, Grunfeld C, and Schambelan M. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86: 3480-3487, 2001.
17. Marks SJ, Moore NR, Clark ML, Strauss BJ, and Hockaday TD. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obes Res 4: 1-7, 1996.
18. Matsuda M and DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22: 1462-1470, 1999.
19. Mulligan K, Grunfeld C, Hellerstein MK, Neese RA, and Schambelan M. Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 77: 956-962, 1993.
20. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, and Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr Hum Retrovirol 25: 312-321, 2000.
21. Nagaretani H, Nakamura T, Funahashi T, Kotani K, Miyanaga M, Tokunaga K, Takahashi M, Nishizawa H, Kishida K, Kuriyama H, Hotta K, Yamashita S, and Matsuzawa Y. Visceral fat is a major contributor for multiple risk factor clustering in Japanese men with impaired glucose tolerance. Diabetes Care 24: 2127-2133, 2001.
22. Panse I, Vasseur E, Raffin-Sanson ML, Staroz F, Rouveix E, and Saiag P. Lipodystrophy associated with protease inhibitors. Br J Dermatol 142: 496-500, 2000.
23. Pascot A, Despres JP, Lemieux I, Almeras N, Bergeron J, Nadeau A, Prud'homme D, Tremblay A, and Lemieux S. Deterioration of the metabolic risk profile in women. Respective contributions of impaired glucose tolerance and visceral fat accumulation. Diabetes Care 24: 902-908, 2001.
24. Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD, and Meinders AE. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab 86: 5509-5515, 2001.
25. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, and Grinspoon S. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86: 504-510, 2001.
26. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, and Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 133: 92-103, 2000.
27. Schwarz JM, Mulligan K, Lee J, Lo JC, Wen M, Noor MA, Grunfeld C, and Schambelan M. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87: 942-945, 2002.
28. Wanke C, Gerrior J, Kantaros J, Coakley E, and Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13: 2099-2103, 1999.